Ad
related to: mitochondrial permeability transition pore assay tool for dogs
Search results
Results From The WOW.Com Content Network
The mitochondrial permeability transition pore (mPTP or MPTP; also referred to as PTP, mTP or MTP) is a protein that is formed in the inner membrane of the mitochondria under certain pathological conditions such as traumatic brain injury and stroke.
Apart from exchange of ADP and ATP across the inner mitochondrial membrane, the ANT also exhibits an intrinsic uncoupling activity [1] [17] ANT is an important modulatory [18] and possible structural component of the Mitochondrial Permeability Transition Pore, a channel involved in various pathologies whose function still remains elusive. Karch ...
During apoptosis, VDAC modifies the mitochondrial permeability transition pore to release of apoptogenic factors such as cytochrome c. However, VDAC are not essential components of the mitochondrial permeability transition pore. Although cytochrome c plays an essential role in oxidative phosphorylation within the mitochondrion.
Examples of mitochondrial transport proteins include the following: The mitochondrial permeability transition pore, which opens in response to increased mitochondrial calcium (Ca 2+) load and oxidative stress [45] The mitochondrial calcium uniporter which transports calcium from the cytosol of the cell into the mitochondrial matrix [45] [46]
PPIF is a major component of the mitochondrial permeability transition pore (MPTP) and, thus, highly involved in mitochondrial metabolism and apoptosis, as well as in mitochondrial diseases and related conditions, including cardiac diseases, neurodegenerative diseases, and muscular dystrophy. [7]
Mitochondrial outer membrane permeabilization (MOMP), also known as the mitochondrial outer membrane permeability, is one of two ways apoptosis (a type of programmed cell death) can be activated. [1] It is part of the intrinsic pathway of apoptosis, also known as the mitochondrial pathway. MOMP is known as the point of no return in apoptosis.
The Bradford protein assay (also known as the Coomassie protein assay) was developed by Marion M. Bradford in 1976. [1] It is a quick and accurate [2] spectroscopic analytical procedure used to measure the concentration of protein in a solution. The reaction is dependent on the amino acid composition of the measured proteins.
The pore size is reduced reciprocally to the %T. Concerning %C, a concentration of 5% produces the smallest pores, since the influence of bisacrylamide on the pore size has a parabola-shape with a vertex at 5%. Gels are usually polymerized between two glass plates in a gel caster, with a comb inserted at the top to create the sample wells.